文献速递胸部CT

COVID-19后肺部影像学后遗症及其与临床和肺功能评估的相关性:前瞻性队列研究结果

Radiological pulmonary sequelae after COVID-19 and correlation with clinical and functional pulmonary evaluation: results of a prospective cohort.
PubMed 文献 · Eur Radiol · 2023-08-12

前瞻性单中心研究纳入2020年3月至5月因COVID-19住院患者,对存在残留症状或曾入住ICU者在出院后4个月行胸部CT和肺功能检查。169例4个月胸部CT中19%(32/169)见肺纤维化病变,9个月和16个月持续率分别为97%(29/30)和95%(18/19);纤维化组一氧化碳弥散量和肺总量显著降低,预测因素为肺栓塞(OR=9.0)、高流量氧疗(OR=6.37)和有创机械通气(OR=3.49)。

要点

  • COVID-19住院患者出院4个月胸部CT肺纤维化病变发生率19%(32/169),9个月和16个月持续率分别为97%(29/30)和95%(18/19)。
  • 纤维化病变不匹配任何间质性肺疾病模式,伴一氧化碳弥散量和肺总量显著降低(均p<0.001),但呼吸困难量表无显著临床差异。
  • 肺栓塞(OR=9.0)、高流量氧疗(OR=6.37)和机械通气(OR=3.49)是影像学肺纤维化病变的预测因素。

核心结论

  • 因COVID-19住院后4个月,19%的受检患者存在影像学肺纤维化病变,且病变持续至16个月。

研究设计与样本

  • 前瞻性单中心队列研究,1151例因COVID-19住院患者中169例在出院后4个月行胸部CT和肺功能检查,部分患者在9个月和16个月复查胸部CT。

关键影像表现/征象

  • 胸部CT显示肺纤维化病变,9个月和16个月持续率分别为97%(29/30)和95%(18/19);纤维化病变不匹配任何间质性肺疾病模式。

诊断标准与关键数值

  • 纤维化组一氧化碳弥散量显著降低(p<0.001),肺总量显著降低(p<0.001);呼吸困难量表无显著临床差异。

临床应用与阅片要点

  • 对COVID-19住院后存在残留症状或曾入ICU者,出院4个月胸部CT可评估肺纤维化病变,并应结合肺功能检查解读。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19.

MATERIALS AND METHODS: We conducted a prospective single-center study among patients hospitalized for COVID-19 between March and May 2020. Patients with residual symptoms or admitted into intensive care units were investigated 4 months after discharge by a chest CT (CCT) and pulmonary function tests (PFTs). The primary endpoint was the rate of persistent radiological fibrotic lesions after 4 months. Secondary endpoints included further CCT evaluation at 9 and 16 months, correlation of fibrotic lesions with clinical and PFT evaluation, and assessment of predictive factors.

RESULTS: Among the 1151 patients hospitalized for COVID-19, 169 patients performed a CCT at 4 months. CCTs showed pulmonary fibrotic lesions in 19% of the patients (32/169). These lesions were persistent at 9 months and 16 months in 97% (29/30) and 95% of patients (18/19) respectively. There was no significant clinical difference based on dyspnea scale in patients with pulmonary fibrosis. However, PFT evaluation showed significantly decreased diffusing lung capacity for carbon monoxide (p < 0.001) and total lung capacity (p < 0.001) in patients with radiological lesions. In multivariate analysis, the predictive factors of radiological pulmonary fibrotic lesions were pulmonary embolism (OR = 9.0), high-flow oxygen (OR = 6.37), and mechanical ventilation (OR = 3.49).

CONCLUSION: At 4 months, 19% of patients investigated after hospitalization for COVID-19 had radiological pulmonary fibrotic lesions; they persisted up to 16 months.

CLINICAL RELEVANCE STATEMENT: Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19. The prevalence of persisting lesions after COVID-19 remains unclear. We assessed this prevalence and predictive factors leading to fibrotic lesions in a large cohort. The respiratory clinical impact of these lesions was also assessed.

KEY POINTS: • Nineteen percent of patients hospitalized for COVID-19 had radiological fibrotic lesions at 4 months, remaining stable at 16 months. • COVID-19 fibrotic lesions did not match any infiltrative lung disease pattern. • COVID-19 fibrotic lesions were associated with pulmonary function test abnormalities but did not lead to clinical respiratory manifestation.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Soliman S, Soliman H, Crézé M, et al. Radiological pulmonary sequelae after COVID-19 and correlation with clinical and functional pulmonary evaluation: results of a prospective cohort. Eur Radiol. 2023. PMID: 37572192. doi:10.1007/s00330-023-10044-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。